within Pharmacolibrary.Drugs.D_Dermatologicals.D04A_AntipruriticsInclAntihistaminesAnestheticsEtc.D04AA01_Thonzylamine;

model Thonzylamine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.4,
    Cl = 2e-06,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.0035,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Thonzylamine</td></tr><tr><td>ATC code:</td><td>D04AA01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>120</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Thonzylamine is a first-generation antihistamine previously used as an antipruritic and for relief of allergy symptoms such as urticaria and rhinitis. Its usage has been largely discontinued and it is not commonly approved or available in modern medical practice.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data in humans are available for thonzylamine. The following values are estimated based on typical first-generation antihistamines of similar class.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D04AA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Thonzylamine;
